Diabetes

POSTERS AT THE 2018 American Association of Diabetes Educators (AADE) Annual Conference covered updates on new therapies and technology, strategies to help patients overcome fear of using insulin, and innovations in diabetes self-management education and support. Following are a few snapshots of the research presented at AADE.

A letter from our Editor-in-Chief, Robert Gabbay, MD, PhD, FACP.

Every week, The American Journal of Managed Care® recaps the top managed care news of the week, and you can now listen to it on our podcast, Managed Care Cast.

Livongo’s technology is built around the idea that a person living with diabetes must make multiple decisions every day, and the cumulative effect of all those decisions drives outcomes.

A profile of a program that calls for residents in a rural area to become full partners in managing their type 2 diabetes, and in the process bring changes to their community.

Employers who have been disappointed in the past with wellness programs want to see evidence of patient engagement and how this translates into savings.

A former president of the American Association of Diabetes Educators addresses the need to remodel diabetes self-management education and support, to create a reimbursement system that better meets the needs of today's providers and patients.

This article is based on a keynote presentation at the 2018 annual conference of the American Association of Diabetes Educators.

There are a growing number of diabetes therapies, which has led to the need to individualize choices based on patient profile, said Robert A. Gabbay, MD, PhD, FACP, senior vice president and chief medical officer of Joslin Diabetes Center.

This week, the top managed care news included comments to several proposals from CMS; Medicare advocates say voters will be motivated by healthcare cost concerns during the midterm elections; research showed diabetes drug dapagliflozin, an SGLT2 inhibitor, reduces risks of major cardiovascular events.

Full results from the cardiovascular outcomes trial for dapagliflozin (Farxiga) will be presented at the American Heart Association annual meeting in November.

In the United States, a woman age 30 to 70 years of age has a 1 in 8 chance of dying from a noncommunicable disease (NCDs), putting the nation on par with low and middle-income countries, and setting it apart with Iceland among high-income countries, according to a report published Thursday in The Lancet.

A series of experiments identified both "good" and "bad" gut bacteria, suggesting possible treatments for obesity.

As September marks National Ovarian Cancer Awareness Month, we sat down with ovarian cancer survivor Marion Roth and Vaagn Andikyan, MD, gynecologic oncologist, Western Connecticut Health Network, to discuss Marion's cancer journey and the importance of a multidisciplinary care team in treating complexities in cancer care.

Among Latino patients with diabetes, ethnicity and language barriers were not associated with lipid and blood pressure control despite their associations with glycemic control in prior research. Check out our website’s new table/figure pop-up feature! Click on the name of a table or figure in the text to see it in your browser.

Fragility fractures are a serious complication of type 1 and type 2 diabetes, but many clinicians who treat patients with diabetes are not aware of the increased risk of these fractures.

Every week, The American Journal of Managed Care® recaps the top managed care news of the week, and you can now listen to it on our podcast, Managed Care Cast.

This week, the top managed care stories included encouraging results from the Next Generation Accountable Care Organization model; concerns that CMS' new billing rules will hurt the sickest patients; a study confirms the value of daily aspirin for patients with diabetes.

The analysis of patient records found no elevated risk of retinopathy among those using glucagon-like peptide-1 (GLP-1) receptor agonists to treat type 2 diabetes.

Serious vascular events in patients with diabetes can be prevented with aspirin use, according to results of the ASCEND (A Study of Cardiovascular Events iN Diabetes) trial, which were presented at the ongoing ESC Congress in Munich, Germany.

A leader at the Institute for Healthcare Improvement offers a framework for diabetes educators to embrace a shift in thinking about healthcare delivery.

Given the high cost of treating diabetes and the large population with prediabetes, prevention has become a point of focus. We’re taking a look back to 2017, when The American Journal of Managed Care® convened a panel of experts to discuss diabetes prevention and the use of technology.

Robert A. Gabbay, MD, PhD, FACP, senior vice president and chief medical officer of Joslin Diabetes Center, explains why the Joslin Diabetes Center and the American Diabetes Association oppose the decision by the American College of Physicians to recommend a higher A1C target across the board.

Patients with type 2 diabetes and moderate renal impairment who took oral semaglutide in a phase 3a trial reported a larger reduction in glycated hemoglobin and more weight loss than patients taking placebo.

Three federal officials discussed the status of research, payer coverage, and referrals for the National Diabetes Prevention Program, as well as the rollout of the Medicare program for eligible seniors.

The rise of digital health alongside the transformation of reimbursement from fee-for-service to value-based care is allowing patients to fully participate in their own care, according to a leader with one of the top digital health companies in diabetes care.

Robert A. Gabbay, MD, PhD, FACP, chief medical officer and senior vice president at Joslin Diabetes Center, said health systems need people with the skill sets that diabetes educators possess to make the transition to a reimbursement system based on quality, prevention, and eliminating costs.